AU572819B2

AU572819B2 – Vascular graft and blood supply method
– Google Patents

AU572819B2 – Vascular graft and blood supply method
– Google Patents
Vascular graft and blood supply method

Info

Publication number
AU572819B2

AU572819B2
AU24182/84A
AU2418284A
AU572819B2
AU 572819 B2
AU572819 B2
AU 572819B2
AU 24182/84 A
AU24182/84 A
AU 24182/84A
AU 2418284 A
AU2418284 A
AU 2418284A
AU 572819 B2
AU572819 B2
AU 572819B2
Authority
AU
Australia
Prior art keywords
blood
passage
graft
restricted
flow
Prior art date
1982-12-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU24182/84A
Other versions

AU2418284A
(en

Inventor
Zinon C.Possis
Demetre M. Nicoloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Medical Care Inc

Original Assignee
Possis Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1982-12-13
Filing date
1983-12-08
Publication date
1988-05-19

1983-12-08
Application filed by Possis Medical Inc
filed
Critical
Possis Medical Inc

1984-07-05
Publication of AU2418284A
publication
Critical
patent/AU2418284A/en

1988-05-19
Application granted
granted
Critical

1988-05-19
Publication of AU572819B2
publication
Critical
patent/AU572819B2/en

2003-12-08
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS

A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

A61F2/02—Prostheses implantable into the body

A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts

A61F2/06—Blood vessels

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC

Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor

Y10S623/902—Method of implanting

Y10S623/903—Blood vessel

Abstract

A vascular graft is used to supply blood to one or more coronary artery branches. The vascular graft has an elongated U-shaped tubular body providing a continuous passage for carrying blood from a high pressure blood supply to a blood receiver. One or more openings in the body allow blood to flow into the coronary artery branches. The flow and pressure of the blood in the passage is controlled by a restriction providing a Venturi passage located remote from the inlet end of the tubular body. The restriction is reinforced with an annular sleeve to maintain a desired cross sectional area and length of the Venturi passage. The pressure differential between the blood supply and blood receiver maintains continuous and adequate blood flow at a desired pressure in the body passage and provides a continual supply of blood for the coronary artery branches.

Description

VASCULAR GRAFT AND BLOOD SUPPLY METHOD FIELD OF INVENTION:
The invention relates to implants used in the body to replace natural blood vessels to supply arterial blood to organs and tissues throughout the body. More parti¬ cularly, the implants are vascular grafts used to supply blood to the tissue. BACKGROUND OF INVENTION:
Congenital defects, disease, or injury can render a person’s blood vessels incapable of serving as an appro¬ priate conduit for blood. Autogenous blood vessels may be relocated from their original site in the person’s body and grafted to a new site as a replacement for the diseased or traumatized native vessel. Synthetic or non- autogenous tissue origin vascular grafts may also be implanted in a person to replace diseased or traumatized native vasculature.
Infection, aneurysm, thrombosis, hyperplastic tissue response, stenosis at the anastomoses, are all problems which occur with any known vascular graft whether it be of autogenous or non-autogenous origin. Long term patency of vascular grafts is dependent upon many factors including the skill of the implanting surgeon, patient health status, quality of the vascular graft and other factors. The influence of any particular factor on successful long term function has not been quantified. However, it is commonly held that low velocity of blood flow and low flow rate are major factors which reduce patency. Conversely then, higher flow rate and higher velocity of flow are major factors which increase patency longevity.
The autogenous saphenous vein is used successfully
OMPI

as a vascular conduit for coronary artery revasculari- zation. Although the search for a suitable prosthetic graft for aortocoronary bypass continues, nothing better than the autogenous saphenous vein is available. Sur- geons have been reluctant to use synthetic grafts in aortocoronary bypass because of few proved instances of long-term patency.
Although saphenous veins are used in aortocoronary bypass procedures, there are certain disadvantages: (1) unavailability, (2) small size, (3) non-uniform caliber, (4) varicosities, (5) large diameter, C6) sclerosis, (7) obstruction due to intimal hyper- plasia, (8) aneurysm formation, (9) considerable time required for harvesting, (10) leg discomfort and swell- ing, and (11) possible leg infection.
A significant number of patients requiring aorto¬ coronary bypass do not have suitable veins, or the veins have been used for previous aortocoronary bypass or for peripheral vascular bypass procedures. On occasion, the need for a graft may have been unforeseen prior to surgery, and the legs not prepared for harvesting of the vein. The cephalic vein from the arm has been used when the saphenous vein is not available. However, it is usually thin-walled and often of poor caliber. Fur- thermore, the cosmetic effect of harvesting the cephalic vein is unacceptable for some patients.
The internal mammary artery is widely accepted as suitable for myocardial revascularization, in that it has an excellent patency ratio, but is useful only for the left anterior descending and diagonal coronary arteries. Experience with free grafts of the internal mammary and radial arteries has been disappointing, since long-term patency has been poor.
The importance of the velocity of blood flow in autogenous vein grafts has been emphasized. There is evidence of an inverse relationship between the veloc¬ ity of blood flow in venous grafts and the amount of intimal proliferation observed. Autopsy studies indi-

cate that occlusion of aortocoronary saphenous vein grafts more than one month after operation is most commonly caused by fibrous intimal proliferation. Although the cause of this lesion has not been defin- itely established, studies would suggest that it is probably related to a low velocity of flow through the graft. This suggests that every effort should be made to achieve a high velocity of flow in coronary artery bypass grafts. Synthetic vascular implants are disclosed by Liebig in U. S. Patents Nos. 3,096,560; 3,805,301 and 3,945,052. These grafts are elongated knit fabric tubes made of yarn, such as polyester fiber. Dardik in U. S. Patent No. 3,894,530 discloses the use of an umbilical cord for a vascular graft. Holman et al in U. S. Patent No. 4,240,794 disclose a method of preparing human and other animal umbilical cords for use as a vascular replacement. The fabric tubes and umbilical cords have been used to replace the saphenous vein implant. The ends of the tubes and cords are anastomosed to ends of arteries to by-pass diseased areas of the arteries. They replace the diseased portions of the arteries. SUMMARY OF INVENTION:
The goal of vascular reconstructive surgery is to effectively supply blood to organs and tissues whose blood vessels integrity are compromised by congenital defects or acquired disorders, such as arteriosclerosis, trauma, and other diseases. The invention is a graft and a method employing the graft for supplying blood to organs and tissues throughout the body.
According to the invention, there is provided a graft for supplying blood to one or more blood receivers, such as blood vessels. The graft includes an elongated means having a continuous passage for carrying blood from a supply of blood under pressure to one or more blood receivers. The elongated means has a body pro¬ viding a first passage for carrying of blood. The body has one or more openings and is connectable to at least

one blood vessel for supplying blood to the opening to the blood vessel. The body has an inlet end means adapted to be connected to a supply of blood under pres¬ sure, whereby blood flows into the first passage and from the first passage into the blood vessel. The flow of blood and pressure of the blood in the first passage is controlled with a means having a restricted second passage connected to the distal portion of the body remote from the inlet end means. An outlet end means connects the means having the restricted second passage to blood receiving means. A pressure differential be¬ tween the blood supply means and the blood receiving means maintains continuous and adequate blood flow at a desired pressure and velocity through the first and second passages and provides a continual supply of blood for the blood vessels that are attached to the body.
The graft is used to supply blood to one or more coronary artery branches in a primate heart. The heart has two atria for receiving blood from the vena cava and pulmonary veins and is connected to an aorta to carry blood under pressure from the heart. The graft comprises an elongated tubular means having a continuous longitudinal passage for carrying blood from the aorta to the atrium or a low pressure blood vessel. The tubular means has an inlet end anastomosed to the aorta so that blood under pressure flows from the aorta into the passage and is discharged through an outlet end into the atrium or other vessel of lower mean pressure than the aorta. The outlet end of the tubular means is anas¬ tomosed to the heart tissue around an opening in communi¬ cation with the atrium. The tubular means has one or more openings used to provide blood to one or more coro¬ nary arteries or branches. The coronary arteries are sutured to the tubular means whereby blood flows through the openings in the tubular means into the coronary artery branches. The flow rate, velocity of flow, and pressure of the blood in the passage is controlled by a restric¬ tion located remote from the inlet end of the tubular

means. The area of restriction is a restricted second passage having a diameter that is less than one-half the diameter of the main or first passage of the tubular means. The restricted passage is also smaller than the passage in the outlet end of the tubular means. The tubular means is generally U-shaped and encircles the critical areas of the heart beginning at the aorta and ending at either the right or left atrium or pulmonary artery. The pressure differential between the aorta and
10 the atrium causes a continuous flow of blood in quanti¬ ties and at velocities that inhibit thrombosis, and provides a continuous supply of blood at a desired pres¬ sure to the arteries connected to the tubular means. In one embodiment of the invention, the tubular ■■-•* means is an elongated synthetic tube, such as a poly- tetrafluoroethylene tube, a Dacron tube, or a tube of other synthetic bioco patible material. The tube is continuous and has a reduced diameter section proximal to the distal or outlet end thereof. The reduced diamete 0 section provides the restricted passage for controlling the blood flow and sustaining the pressure of the blood in the first passage of the tubular means. The restrict¬ ed passage also controls the flow and velocity of blood moving through the outlet end of the tubular means. 5 A second embodiment of the invention utilizes a human umbilical cord or other tissue tubes of any origin as the elongated means. The umbilical cord can be linear or shaped to encircle the critical areas of the heart. The outlet or distal end portion of the cord has a reduc¬ 0 ed diameter to provide a restricted passage for the flow of blood through the cord. Selected arteries are anas¬ tomosed to the body of the cord and are provided with openings whereby blood from the lumen of the cord can flow into the arteries. 5
In a third embodiment of the invention, the elon¬ gated tubular means comprises an autogenous saphenous vein having a large enough caliber to assure adequate blood flow. The vein encircles the heart from the
OMPI

aorta and extends to the atrium. The distal or outlet end section of the vein accommodates an adjustable blood flow restrictor operable to reinforce the vein and reduce the cross sectional area of the vein passage to form a restricted passage. The restricted passage controls the flow of blood in the vein passage while maintaining a continuous flow of blood at a desired pressure. Selected portions of the vein are anastomosed to coronary arteries to provide continuous flow of blood to these arteries. According to a fourth embodiment of the invention, there is provided a graft for supplying blood to one or more blood receivers, such as blood vessels. The graft includes an elongated tubular means having a continuous passage for carrying blood from a supply of blood under pressure to one or more blood vessels and blood receiver means. The flow of blood, velocity of blood flow, and pressure of the blood in the continuous passage is con¬ trolled with reinforced means having a restricted pass¬ age connected to the distal portion of the elongated tubular means remote from the inlet end means. The reinforced means maintains the cross sectional and longitudinal dimensions of the restricted passage over an extended period of time. The reinforcing means has an annular reinforcing sleeve surrounding the body to maintain the shape and size of the restricted passage. Other means can be used to reinforce the tubular means to ensure the shape and size of the restricted passage. The reinforcing means can be an increased wall thickness of the tubular means surrounding the restricted passage, or thread or tape surrounding the tubular means. An outlet end means connects the reinforced means having the restricted passage to blood receiving means. The outlet end means has an outlet passage larger than the restricted passage so as to reduce the velocity and pres- sure of the blood flowing into the atrium or low pressure blood vessel. A pressure differential between the blood supply means and the blood receiving means maintains continuous and adequate blood flow at a desired pressure
OMPI

through the passages and provides a continual supply of blood for the blood vessels that are attached to the elongated tubular means over a long period of time. The elongated tubular means can be.an autogenous blood vessel or a synthetic tube, such as a polytetra- fluoroethylene tube, a Dacron tube, or a tube of other bioco patible material. The tube is continuous and has a reduced cross sectional area or throat section proximal to the distal or outlet end thereof. An elongated annula sleeve of reinforcing material surrounds the throat sec¬ tion to maintain the cross sectional area of the restrict ed passage through the throat section. The reinforcing material can be a fiber plastic, fiber mesh, a carbon tubular member, or metal tubular member attached to the outside of the throat section. The fiber can comprise a plurality of substantially non-elastic interconnected strands or wire-like members of metal, plastic, or carbon The reinforcing material can be incorporated into the material of the throat section. The reinforcing material can be thread or tape wound around the throat section.
A sleeve of rigid material, such as molded plastic, metal or carbon can be located about the throat section. The wall thickness of the throat section can be enlarged to provide for reinforcement thereof. The reduced cross sectional area provides a restricted passage for control¬ ling the blood flow and sustaining the pressure of the blood in the first passage of the tubular means.
A fifth embodiment of the invention utilizes a human umbilical cord or autogenous blood vessel as the elongated means for carrying blood to the blood receiving vessels. The outlet or distal end of the cord has a reduced size to provide a restricted passage for control¬ ling the flow, velocity and pressure of blood through the cord. The size of the restricted passage is maintained with an annular sleeve of reinforcing material mounted on the umbilical cord. The reinforcing material can be a fiber plastic, tape, a carbon tubular member, or metal tubular member surrounding a distal section of the

umbilical cord. Selected arteries are anastomosed to the body of the cord and are provided with openings whereby blood from the lumen of the cord flows into the arteries. The invention includes a method of providing a con¬ tinuous supply of flowing blood at a desired pressure to one or more blood receiving vessels, such as coronary arteries of a primate. A graft having a blood flow res¬ tricting passage in the distal end section thereof is anastomosed to the aorta. The graft is placed adjacent the heart to locate portions thereof in proximity to selected coronary branch arteries. Selected portions of the graft are anastomosed to coronary arteries. The distal end of the graft is anastomosed to the atrium or low blood pressure section of the blood circulatory system. Blood under pressure continuously flows from the aorta into the graft, since there is a substantial blood pres¬ sure difference between the aorta and atrium. The res¬ tricted passage prevents the flow of blood from being excessive and maintains the blood pressure in the graft passage at substantially the same as the aorta blood pressure and controls the pressure and velocity of blood flowing from out of the graft to a low pressure vessel or atrium. The coronary arteries are perfused with sufficient quantities of blood. IN THE DRAWINGS:
Figure 1 is an anterior view of a human heart; Figure 2 is a schematic longitudinal sectional diagram of the heart of Figure 1; Figure 3 is an anterior view of a human heart having the graft of the invention;
Figure 4 is an enlarged partly sectioned plan view of the graft of Figure 3;
Figure 5 is an enlarged sectional view taken along the line 5-5 of Figure 4;
Figure 6 is an enlarged sectional view taken along the line 6-6 of Figure 4;
Figure 7 is an enlarged sectional view taken along
O PI

the line 7-7 of Figure 4;
Figure 8 is an enlarged sectional view taken along the line 8-8 of Figure 4;
Figure 9 is an enlarged sectional view taken along the line 9-9 of Figure 3;
Figure 10 is an enlarged sectional view taken along the line 10-10 of Figure 3;
Figure 11 is an enlarged sectional view taken along the line 11-11 of Figure 3; Figure 12 is a plan view, partly sectioned, of a saphenous vein and distal and tubular blood flow restrictor anastomosed to the vein, usable as a graft of the invention;
Figure 13 is an enlarged sectional view taken along the line 13-13 of Figure 12;
Figure 14 is an enlarged sectional view taken along the line 14-14 of Figure 12;
Figure 15 is an enlarged sectional view taken along the line 15-15 of Figure 12; Figure 16 is an enlarged sectional view taken along the line 16-16 of Figure 12;
Figure 17 is an enlarged sectional view taken along the line 17-17 of Figure 12;
Figure 18 is a plan view, partly sectioned, of a graft and adjustable blood flow restrictor therefor;
Figure 19 is an enlarged sectional view taken along the line 19-19 of Figure 1;
Figure 20 is an enlarged sectional view taken along the line 20-20 of Figure 18; Figure 21 is an enlarged sectional view taken along the line 21-21 of Figure 18;
Figure 22 is an enlarged sectional view taken along the line 22-22 of Figure 18
Figure 23 is an anterior view of a human heart having a reinforced vascular graft of the invention;
Figure 24 is an enlarged partly sectioned plan view of the vascular graft of Figure 23;
Figure 25 is an enlarged sectional view taken along
OMPI

the line 25-25 of Figure 24;
Figure 26 is an enlarged distal end view of the vascular graft of Figure 24;
Figure 27 is an enlarged sectional view taken along the line 27-27 of Figure 26;
Figure 28 is an enlarged sectional view taken along the line 28-28 of Figure 26;
Figure 29 is an enlarged sectional view taken along the line 29-29 of Figure 26; Figure 30 is an enlarged sectional view taken along the line 30-30 of Figure 26;
Figure 31 is an enlarged sectional view taken along the line 31-31 of Figure 26; and
Figure 32 is an enlarged sectional view taken along the line 32-32 of Figure 26.
DESCRIPTION OF PREFERRED EMBODIMENTS:
Referring to Figures 1, 2 and 3, there is shown an anterior view of a human heart indicated generally at
10. Heart 10 has a right atrium 11, right ventricle 12, left atrium 13, and left ventricle 14. Blood from the body flows through vena cava 16 into right atrium
11. The pressure of the blood in right atrium 11 is low as the blood flows into atrium 11. A heart valve 17 controls the flow of blood from atrium 11 into right ventricle 12. The blood is pumped from right ventricle 12 through valve 18 into pulmonary artery 19, which is connected to the lungs. The blood returns from the lungs via the pulmonary vein 20 to left atrium 13. The blood flows from left atrium 13 through heart valve 21 into a left ventricle 14 and is pumped from the left ventricle 14 through valve 22 into aorta 23. The pres¬ sure differential of the blood between aorta 23 and the atrium 11 is approximately 90 mm Hg. The muscle tissue of the heart is provided with a supply of blood from two coronary arteries 24 and 26. Left coronary artery – 24 extends from aorta 23 along the left side of the heart toward the apex 27. Coronary artery 24 has a number of branches 28, 29, 30 and 31, which supply

blood to the muscle tissue. Left coronary artery 24 has a short common stem which bifurcates or trifurcates into branches 28-31. One branch 31, the anterior inter- ventricular branch, moves downward to the anterior interventricular groove and rounds the acute margin of the heart just to the right of apex 27 and ascends a short distance up the posterior interventricular groove Portions of the branch 31 anastomose with branches from the right coronary artery. These branches are very small in normal hearts. They may enlarge considerably in persons suffering from coronary arteriosclerosis in whom coronary arterial branches become obstructed or occluded. The right coronary artery 26 extends down the right side of the heart toward the apex or crux 27. Artery 26 has a number of branches 32, 33, 34 and 35, which feed blood to the heart tissue.
The right coronary artery 26 arises from the right anterior sinus of aorta 23 and runs along the right atrioventricular sulcus . It rounds the acute margin to reach the crux. It has a number of branches 32-35 to the anterior right ventricle wall. The right arterial branches of the right coronary artery 26 originate from the right coronary artery shortly after its take-off and ascends along the anteromedial wall of the right atrium. Variations of the branching pattern of the arteries 24 and 26 are common in the human heart. In about 67% of the cases, the right coronary artery 26 is dominant and supplies part of the left ventricle wall and ventricle septum. In 15% of the cases, the left coronary artery 19 is dominant and supplies all of the left ventricle and the ventricle septum, and part of the right ventricle wall, with blood. In about 18% of the cases, both coronary arteries 24 and 26 reach the crux 27. It is common for the first, second and third branches of the right coronary artery 26 to originate independently from the right sinus, rather than the parent artery. The graft of the invention can be used to provide an adequate supply of blood to these arteries.
JtJ E O PI

Referring to Figures 4-8, there is shown a vascular graft of the invention indicated generally at 36. Graft 36 is an elongated member 37 having a generally U-shape and a continuous passage for carrying blood. Member 37 has a continuous cylindrical wall 38 having an inside surface 39 forming an elongated longitudinal passage 40. Tubular member 37 has a proximal aortic or inlet end 41 and a distal atrial or outlet end 42. A main generally U-shaped trunk 43 extends from inlet end 41 to a res- tricted or reduced diameter section 44. Restricted section 44 is connected to a distal end section 46. Preferably, restricted section 44 is about 2 to 5 cm from outlet end 42 when it is attached to the heart tissue. As shown in Figures 5-7, restricted section 44 has a cylindrical wall 47 integral with cylindrical wall 38 of the main trunk 43 and atrial end section 46. Wall 47 surrounds a throat passage 48 having a cross sectional area substantially smaller than the cross sectional area of passage 40. The cross sectional area of passage 40 is preferably more than four times larger than the cross sectional area of throat passage 48. Cylindrical wall 47 is joined to wall 38 with a converging conical wall portion 49 which directs the flow of blood into passage 48. The opposite ends of wall 47 are joined to a diverging conical wall portion 51 forming part of the atrial end section 46. Wall portion 51 surrounds an outlet passage 52 leading to the distal outlet end 42. The cross sectional area of outlet passage 52 is substan¬ tially the same as the cross sectional area of passage 40 of main trunk 43. The cross sectional area of outlet passage 52 can be larger than the cross sectional area of passage 40. Conical wall portions 49 and 51 each have a longitudinal length and an inside wall surface that has a gradual smooth taper to minimize turbulence in the blood flow. Preferably, cylindrical wall 47 surround¬ ing passage 48 has a longitudinal length that is shorter than the longitudinal length of the wall portions 49 and 51. Other length and size relationships can be used.
OMH

The longer the length of restriction section 44, the greater the blood pressure drop for a given cross sec¬ tional area of passage 48. Passage 52 provides a chamber wherein the velocity of the blood flow and blood pressure are decreased before it flows into the atrium of the hear Distal end section 46 is of a size to permit easy attach¬ ment thereof to the heart tissue or blood receiving vesse
The entire member 37 is a tubular structure, prefer¬ ably made from a human umbilical cord. The umbilical cord can be pre-curved and tapered to form the desired restricted section 44 by processing. The tubular struc¬ ture can be made from other tissue, including but not limited to a bovine carotid artery, an ovine subcutaneous mandrel grown tubular member, a feline esophagus and feline intestines. Other tubular structures, such as a polytetrafluoroethylene tube or other synthetic tube, can be used for vascular graft 36.
Referring to Figure 3, vascular graft 36 is located adjacent the heart 10. Body 43 descends toward the mid- portion on the anterior surface of the heart and then encircles about to the posterior surface and ascends toward the right atrium. Restricted section 44 and atrial end section 46 are located adjacent atrium 11. As shown in Figure 9, proximal or aortal end 41 of tubu- lar member 37 is implanted into an aortic ostium 53 and anastomosed thereto with sutures 54. As shown in Figure
10, the outlet or atrial end 46 is implanted into an ostium 56 in heart 10 open to atrium 11 and anastomosed thereto with sutures 57. The blood continuously flows through passage 40 of tubular member 37, by reason of the blood pressure difference between aorta 23 and atrium
11. Restricted passage 48 prevents the flow of blood through passage 40 from being excessive. The distal end section 46 of tubular member 37 can be anastomosed to the left atrium 13, whereby the blood flows from aorta 23 through passage 40 and tubular member 37 and into left atrium 13.
The body 43 of graft 36 is located adjacent one

or more of the coronary branches 28-31 and 32-35. The surgeon has the option to anastomose and, therefore, perfuse one or more of the coronary branches along the path of the graft 36. Referring to Figure 11, graft 36 is anastomosed to coronary branch 35 with sutures 58. The cylindrical wall 38 is provided with an opening 59 to allow blood to flow from passage 40 into the coronary artery passage 61. The restricted passage 48 adjacent the atrial end of the graft allows the coronary arteries to be perfused with sufficient quantities of blood at pressures within a few mm Hg of the aortic blood pressure. The flow of blood through restriction 48 is laminar and continues as a laminar flow through the passage 52 into atrium 11. There is a minimum of turbulence of the blood in graft 36. ” The interior surface 39 of the tubular member 37 is smooth and continuous. It does not have any nitrics which can stagnate and coagulate the blood.
Ai adequate flow of blood through the graft passage Ϊ0 is insured by the diameter of the aortic anastomosis 53 of approximately 2500 ml per minute. Tests indicate thai using a 5 mm diameter tubular graft with a simulated aortic flow of approximately 6000 ml per minute and pressure of 100 mm Hg, approximately 500 ml per minute will flow through a 2 mm restriction into the right atrium. Since the cardiac output is limited only by the venous return, the left ventricle will have an additional load of about 8 per cent. Each coronary artery supplied with blood will require about 50 to 150 ml per minute of blood for adequate perfusion. Since the blood flow through an unrestricted 5 mm graft anastomosed to an aorta with blood flowing at 6000 ml per minute will pro¬ vide blood flow well in excess of 2000 ml per minute, an adequate blood supply is available for up to 10 coronary branches, each carrying 150 mm per minute. Calculations of blood flow through the throat passage 48 show a
Reynold’s range of between 500 and 1000. The blood flow is laminar in passages 40 and 48.
In certain cases, a surgeon may choose to use the
OMH

autogenous saphenous vein in lieu of synthetic graft 36 over the umbilical cord, as described herein. Re¬ ferring to Figures 12-17, there is shown a segment of an autogenous saphenous vein indicated generally at 70 comprising an elongated member 71. Member 71 has a continuous cylindrical wall 72 surrounding a passage or lumen 73 for accommodating flowing blood. The inlet or proximal end 74 of member 71 has an opening 75. The saphenous vein 70 follows a path about the heart to reach occluded arteries in the manner of graft 36, as shown in Figure 3. Lumen 73 has a generally uniform diameter from the inlet or aorta end 74 to the distal end 76.
A blood flow restrictor or tubular segment indicated generally at 77 is anastomosed to distal end 76 of vein 70. Blood flow restrictor 77 has an inlet end section 78 and an outlet end section 79 joined to an intermed¬ iate throat section 81. Section 78 has an inlet passage 82 longitudinally aligned with lumen 73. Inlet passage 82 communicates with a restricted passage 83 in throat section 81. Passage 83 opens to an outlet passage 84 in outlet end section 79. The cross sectional area of out¬ let passage 84 is substantially the same as the cross sectional area of the inlet passage 82. The size of restricted passage 83 canvary relative to the size of inlet passage 82. Preferably, the diameter of inlet passage 82 is more than twice the diameter of restricted passage 83. The cross sectional area of passage 82 is more than four times the cross sectional area of throat passage 83. Passage 83 allows blood to continuously flow through lumen 73 at a desired blood pressure in lumen 77 so that one or more coronary arteries can be perfused. The distal or atrial end section 79 has an open outlet 86 allowing blood to flow into the atrium of the heart when section 79 has been anastomosed to the atrium section of the heart.
In use, the surgeon harvests a section of the saphenous vein from the leg of the patient. A blood flow restrictor 77 having the desired size restricted passage
-^U £

83 is secured with sutures 87 to distal end 76 of tubular member 71. The aortal end 74 is anastomosed to aorta 23. Tubular member 71 encircles the heart to locate atrium end 79 of restrictor 77 adjacent atrium 11. End 79 is anastomosed to the atrium section of the heart so that a continuous and adequate flow of blood is main¬ tained through tubular member 70 and restrictor 77. The blood is at a desired pressure so that one or more coron¬ ary arteries can be perfused. The surgeon can anastomose one or more coronary arteries along the path of tubular member 70 in a manner, as shown in Figure 11. This allows the continuous flow of blood under pressure from passage 73 into the lumen of the coronary arteries.
Referring to Figures 18-22, there is shown a tubular graft indicated generally at 90 usable to continuously supply blood to one or more coronary arteries of a human heart. Graft 90 has an elongated generally U-shaped member 91 having a continuous cylindrical wall 92. Wall 92 forms a generally uniform diameter passage 93. Member 91 has an aortic or proximal end 94 having an inlet open¬ ing 96 for receiving a continuous supply of blood from the aorta. The blood flows through passage 93 to a distal end 97 having an outlet opening 98. Distal end 97 is adapted to be anastomosed to the atrium section of the heart or a vein to receive blood therefrom.
As shown in Figures 18-22, an adjustable blood flow restrictor indicated generally at 99 is mounted on member 91 adjacent distal end 97 for restricting the flow of blood into distal end 97 while maintaining a continuous and adequate flow of blood at a desired pressure so that one or more coronary arteries can be perfused. Restrictor 99 also reinforces the tubular member forming the restricted passage. Blood flow restrictor 99 is a clamp unit having a first member 101 adjustably connected to a second member 102 with a pair of self-locking screws 103 and 104. Member 101 has an outwardly curved center section 101A located about an arcuate sector of member 91. Second member 102 has an oppositely outwardly curved

center section 102A facing the curved center section 101A and engageable with an arcuate segment of member 91. Screws 103 and 104 are adjustable to move the first and second members 101 and 102 toward each other to adjust the size of the restricted passage 106, thereby adjust¬ ing the rate of flow of blood through passage 93 and adjusting the pressure of the blood in passage 93. A cylindrical mandrel having a desired cross sectional area is used to provide the restricted passage with a desired size or cross sectional area. The mandrel is inserted into the distal end section of member 91. Restrictor 99 is placed over the distal end section and clamped onto member 91. The curved center sections 101A and 102A move toward each other and force the wall of the member about the mandrel. This mandrel is then removed from the member 91. Restrictor 99 maintains the selected cross section of passage 106, as shown in Figure 22.
Referring to Figure 23, there is shown an anterior view of a human heart indicated generally at 210. Heart 210 has a right atrium 211, right ventricle 212, left atrium.213, and left ventricle 214. Blood from the body flows through vena cava 216 into right atrium 211. The pressure of the blood in right atrium 211 is low as the blood flows into atrium 211. A heart valve controls the flow of blood from atrium 211 into right ventricle 212. The blood is pumped from right ventricle 212 through a valve into pulmonary blood returns from the lungs via the pulmonary vein to left atrium 213. The blood flows from left atrium 213 through the heart valve into a left ventricle 214 and is pumped from the left ventricle 214 through the valve into aorta 223. The muscle tissue of the heart is provided with a supply of blood from two coronary arteries 224 and 226. Left coronary artery 224 extends from aorta 223 along the left side of the heart toward apex 227. Coronary artery 224 has a number of branches 228, 229, 230 and 231, which supply blood to the muscle tissue. Left coronary artery 224 has a short common

stem which bifurcates or trifurcates into branches 228-
231. One branch 231, the anterior interventricular branch, moves downward to the anterior interventricular groove and rounds the acute margin of the heart.just to the right of apex 227 and ascends a short distance up the posterior interventricular groove. Portions of branch 231 anasto¬ mose with branches from the right coronary artery. These branches are very small in normal hearts. They may en¬ large considerably in persons suffering from coronary arteriosclerosis in whom coronary arterial branches be¬ come obstructed or occluded. The right coronary artery 226 extends down the right side of the heart toward apex or crux 227. Artery 226 has a number of branches
232, 233, 234 and 235, which feed blood to the heart tissue.
Referring to- Figures 24-28, there is shown a rein¬ forced vascular graft of the invention indicated generally at 236. Graft 236 is an elongated tubular member 237 having a generally U-shape and a continuous passage 240 for carrying blood. Member 237 has a continuous cylin¬ drical wall 238 having an inside surface 239 forming elongated longitudinal passage 240. Tubular member 237 has a proximal aortic or inlet end 241 and a distal atrial or outlet end 242. A main trunk 243 extends from inlet end 241 to a restricted or reduced section indicated generally by member 244. Restricted section 244 is connected to a distal end section 246. Preferably, restricted section 244 is about 2 to 5 cm from outlet end
242 when it is attached to the heart tissue. As shown in Figures 25-27, restricted section 244 has a cylindrical wall 247 integral with cylindrical wall 238 of main trunk
243 and atrial end section 246. Wall 247 surrounds a restricted passage 248 having a cross sectional area sub¬ stantially smaller than the cross sectional area of passage 240. The cross sectional area of passage 240 is preferably more than four times larger than the cross sectional area of restricted passage 248. Cylindrical wall 247 is joined to wall 238 with a converging conical
OMPI

wall portion 249 which directs the flow of blood into passage 248. The opposite ends of wall 247 are joined to a diverging conical wall portion 251 forming, part of the atrial end section 246. Wall portion 251 surrounds an outlet passage 252 leading to the distal outlet end 242. The cross sectional area of outlet passage 252 is substantially the same as the cross sectional area of passage 240 of main trunk 243. Conical wall portions 249 and 251 each have a longitudinal length and an inside wall surface that has a gradual smooth taper to minimize turbu¬ lence in the blood flow. Preferably, cylindrical wall 247 surrounding passage 248 has a longitudinal length that is shorter than the longitudinal length of the wall portions 249 and 251. Other length and size relationships can be used. The longer the length of restricted section 244, the greater the blood pressure drop for a given cross sectional area of passage 248. Passage 252 provides a chamber wherein the velocity of the blood flow is de¬ creased before it flows into the atrium of the heart. Distal end section 246 is of a size to permit easy attachment thereof to the heart tissue or blood receiving vessel.
Vascular graft 236 is an elongated tube of synthetic material that is biologically inert and does not deter¬ iorate in the body over an extended period of time. Examples of suitable materials are Polytet^afluoroethy- lene and Dacron plastics. Other materials and combina¬ tions of materials can be used for vascular graft 236. The restricted section 244 is reinforced with a sleeve 245 to insure that the cross sectional area and length of passage 248 is maintained over a long period of time. The material of wall 247 does not expand in use when reinforced with sleeve 245 whereby the size and length of passage 248 is kept substantially constant during use of vascular graft 236. Sleeve 245 is a reinforcing structure for wall 247 to inhibit its dilation or expan¬ sion, contraction, and elongation so as to maintain desired dimensions of passage 248 over an extended period of time. This insures continuous and controlled flow of
OM

blood through vascular gra t 236 an ma nta ns t e pres¬ sure of blood in passage 240 at a level to perfuse the coronary branches attached to trunk 38. Sleeve 245 can be a tubular fiber member of metal, plastic, or carbon fibers formed into a mesh surrounding restricted section 244. Tape and thread can be used to form sleeve 245. Sleeve 245 can be bonded or otherwise secured to the outer surface of restricted section 244. Reinforcing structure can be incorporated into the material of res- tricted section 244. The thickness of the wall of the restricted section can be increased to strengthen the restricted section. The sleeve can be a rigid plastic carbon or metal tubular member located about the res¬ tricted section. As shown in Figures 24, 26, 29 and 31, sleeve 245 surrounds wall 247 and conical wall portions 249 and 251 joined to wall 247. Sleeve 245 is continuous from conical wall portion 249 to conical wall portion 251 so as to reinforce both converging and diverging portions of the walls forming the restricted passage 248.
The entire vascular graft 236 can be a tubular struc¬ ture, made from a human umbilical cord. The umbilical cord is cured and tapered to form the desired restricted section 244. The restricted section is reinforced with mechanical reinforcing means as described herein. Other types of blood vessels and tissue tubes provided with a reinforced restricted section can be used as the graft.
Referring to Figure 23, vascular graft 236 is located adjacent heart 210. Body 243 descends toward the mid- portion on the anterior surface of the heart and then encircles about to the posterior surface and ascends toward the right atrium. Restricted section 244 and atrial end section 246 are located adjacent atrium 211. As shown in Figure 30, proximal or aortal end 241 of tubular member 237 is implanted into an aortic ostium
253 and anastomosed thereto with sutures 254. As shown in Figure 31, the outlet or atrial end 246 is attached to the heart 30 around ostium 256 open to atrium 211
OMPI

and anastomosed thereto with sutures 257. The blood continuously flows through passage 240 of tubular member 237, since the blood pressure difference between aorta 223 and atrium 211 is about 90 mm Hg. Restricted passage 248 prevents the flow of blood through passage 240 from being excessive. Restricted section 244 reinforced with sleeve 245 maintains a controlled flow of blood through passage 248. The cross sectional area and length of passage 248 is retained during prolonged use by the reinforcing sleeve 245 in cooperation with wall 247. The distal end section 246 of tubular member 237 can be anas¬ tomosed to left atrium 213, whereby the blood flows from aorta 223 through passages 240, 248 and 252 and into left atrium 213. The body 243 of vascular graft 236 is located ad acent one or more of the coronary branches 228 to 231 and 232 to 235. The surgeon has the option to anastomose and, therefore, perfuse one or more of the coronary branches along the path of vascular graft 236. Referring to Figure 31, vascular graft 236 is anastomosed to coronary branch 235 with sutures 258. The cylindrical wall 238 is provided with an opening 259 to allow blood to flow from passage 240 into the coronary artery passage 261. The restricted passage 248 adjacent the atrial end of the vascular graft allows the coronary arteries to be perfused with sufficient quantities of blood at pressures within a few mm Hg of the aortic blood pressure. The flow of blood through restriction 248 is laminar and con¬ tinues as a laminar flow through the passage 252 into atrium 211. The outlet end passage 252 being larger than the restricted passage 248 reduces the pressure of the blood and velocity of the blood before it flows into atrium 211. There is a minimum of turbulence of the blood in graft 236. The interior surface 239 of the tubular member 237 is smooth and continuous. It does not have any nitrics which can stagnate and coagulate the blood.
The grafts of the invention can be used to carry blood in peripheral revascularization procedures of the

lower extremities. For example, the graft would be inter¬ posed between the most distal arterial anastomosis and the popliteal vein or one of its major branches. The source of blood would be the femoral artery and the anastomosis would be made in the popliteal artery and/or its distal branches, the anterior tibia, posterior tibia, or peroneal arteries. The blood flow restricting passage or throat passage located between these arteries and the distal end of the graft controls the blood flow through the graft. The control of blood flow allows adequate perfusion of blood pressure to these arteries and at the same time insures continuous blood flow to maintain patency of the graft.
While there has been shown and described the prefer- red embodiments of the graft of the invention, and method of supplying a continuous blood flow to one or more arteries, it is understood that changes in the materials, size, length of the graft, and location of the graft may be made by those skilled in the art without departing from the invention. The invention is defined in the following claims .

Claims (1)

1. A graft for supplying blood to coronary arteries of a primate heart having an atrium, pulmonary artery, and an aorta joined to the heart to receive blood there¬ from comprising: an elongated means having a continuous passage for carrying blood, said means having an inlet end attachable to the aorta whereby blood under pressure flows from the aorta into said passage, and an outlet end attachable to the heart to discharge blood into the atrium, said means being provided with one or more open¬ ings and being attachable to one or more arteries whereby blood flows from said passage through said openings into one or more of said arteries, and means for restrict¬ ing the flow of blood and sustaining the pressure of the blood in said passage located remote from the inlet and thereby maintaining a continuous flowing supply of blood to said arteries.
2. The graft of claim 1 wherein: said elongated means has a generally U-shaped tubular body.
3. The graft of claim 1 wherein: said elongated means and means for restricting the flow of blood com¬ prises a synthetic tube.
4. The graft of claim 1 wherein: said elongated means and means for restricting the flow of blood com¬ prises an umbilical cord.
5. The graft of claim 4 wherein: the umbilical cord has a distal end section, said distal end section having a throat passage smaller in size than the passage in the elongated means to sustain the pressure of the blood in the passage of the elongated means and restrict the amount of blood that flows through said passage in the elongated means.
6. The graft of claim 5- wherein: said throat passage is spaced upstream from the distal end of the umbilical cord.

. e gra o c a m nc u ng: means o a e about a distal end section of the cord for reducing the cross sectional area of the passage of the cord to res¬ trict the amount of blood that flows through said passage of the cord.
8. The graft of claim 7 wherein: the means located about a distal end section of the cord comprises clamp means engageable with the cord.
9. The graft of claim 8 wherein: said clamp means includes means for adjusting the cross sectional area of the throat passage.
10. The graft of claim 1 wherein: said elongated means is a saphenous vein, and the means for restricting the flow of blood is attached to the outlet end of the saphenous vein.
11. The graft of claim 10 wherein: said means for restricting the flow of blood comprises tubular means having a throat passage with a cross sectional area smaller than the cross sectional area of the passage of the saphenous vein to restrict the flow of blood therein.
12. The graft of claim 11 wherein: the cross sec¬ tional area of the throat passage is less than one-half of the cross sectional area of the passage of the saphen¬ ous vein.
13. The graft of claim 1 wherein: said elongated means has a cylindrical wall having an inside cylindri¬ cal surface surrounding said passage, said wall being provided with said openings to feed blood to said arteries.
14. The graft of claim 13 wherein: said inside cylindrical surface has a generally uniform diameter.
15. The graft of claim 13 wherein: said means for restricting the flow of blood in said passage comprises a section of said cylindrical wall having an inside cross sectional area smaller than the cross sectional area of said passage thereby providing said passage with a throat.

16. The graft of claim 15 wherein: said cylindrical wall has an outlet end portion connected to said section, said portion having an outlet passage for carrying blood from the throat to the atrium.
17. The graft of claim 16 wherein: said outlet end portion has a length of less than 10 cm.
18. The graft of claim 16 wherein: said cylindrical wall has a generally U-shape.
19. The graft of claim 15 wherein: said passage has a diameter of about 5 mm and the throat has a diameter of about 2 mm.
20. The graft of claim 15 wherein: said throat has a cross sectional area that is less than one-half the cross sectional area of the passage.
21. The graft of claim 16 wherein: said outlet passage has a cross sectional area larger than the cross sectional area of the throat.
22. The graft of claim 1 including: means for re¬ inforcing the means for restricting the flow of blood to maintain the size and shape thereof.
23. The graft of claim 1 wherein: said means for reinforcing the means for restricting the flow of blood comprises an annular sleeve.
24. The graft of claim 23 wherein: the sleeve comprises fiber means providing a reinforcement.
25. The graft of claim 24 wherein: the fiber means comprise a plurality of substantially non-elastic strands.
26. The graft of claim 1 wherein: said means for restricting the flow of blood comprises tubular means having a restricted passage with a cross sectional area smaller than the cross sectional area of the continuous passage to restrict the flow of blood through the res¬ tricted passage, said means for reinforcing the means for restricting the flow of blood comprising a sleeve surrounding the tubular means forming the restricted passage.

27. The graft of claim 26 wherein: said elongated means and means for restricting the flow of blood com¬ prises a synthetic tube having a restricted section pro¬ viding a restricted passage, and said means for reinforc¬ ing the means for restricting the flow of blood comprises a sleeve located about and mounted on the restricted section.
28. The graft of claim 26 wherein: said elongated means, and means for restricting the flow of blood com¬ prises an umbilical cord having a restricted section providing a restricted passage, and said means for reinforcing the means for restricting the flow of blood comprises said sleeve located about and mounted on the restricted section.
29. The graft of claim 22 wherein: said means for restricting the flow of blood and sustaining the pressure of the blood in said passage comprises a tubular wall joined to a converging wall and a diverging wall, said means for reinforcing the means for restricting the flow of blood comprising a tubular sleeve surround¬ ing and mounted on the tubular wall, converging wall, and diverging wall.
30. The graft of claim 26 wherein: said elongated means comprises a synthetic tube having a restricted section providing a restricted passage, said restricted section having enlarged wall thickness to reinforce the restricted section.
31. A graft for supplying blood to one or more blood vessels comprising: an elongated means having an inlet end means adapted to be connected to means providing a supply of blood under pressure, a tubular body having a first passage adapted to be provided with one or more openings and connected to at least one blood vessel for supplying blood to said vessel, means having a res¬ tricted second passage connected to said body remote from said inlet end to control the flow of blood through the first passage and sustain the pressure of blood in the first passage, and an outlet end connected to the

eans having a restricted second passage adapted to be connected to a receiver of blood having blood pressure lower than the pressure of the supply of blood.
32. The graft of claim 31 wherein: said body has a generally U-shape.
33. The graft of claim 31 wherein: said body means having a restricted second passage and an outlet end comprise a synthetic tube.
34. The graft of claim 31 wherein: said body means having a restricted second passage and an outlet, and said body including an umbilical cord.
35. The graft of claim 31 wherein: said body is a saphenous vein, and the means for controlling the flow of blood through the first passage is attached to the outlet end of the saphenous vein.
36. The graft of claim 35 wherein: said means for controlling the flow of blood comprises a body having said restricted second passage, and means connectable to the saphenous vein.
37. The graft of claim 31 wherein: said means having a restricted second passage is located adjacent said outlet end.
38. The graft of claim 37 wherein: said means having a restricted second passage is located within 10 cm of said outlet end.
39. The graft of claim 31 wherein: said means having a restricted second passage includes clamp means located about a distal section of said body for reducing the size of said distal section thereby providing said second passage.
40. The graft of claim 39 wherein: said clamp means includes means for adjusting the clamp means to vary the size of said distal section thereby adjusting the size of said second passage.
– TRlX£*
OMPI _

41. The graft of claim 31 wherein: said second passage has a cross sectional area that is less than one-half the cross sectional area of the first passage.
42. The graft of claim 31 wherein: said outlet end has a third passage having a cross sectional area larger than the cross sectional area of said restricted second passage.
43. The graft of claim 31 including: reinforcing means cooperating with the means having a restricted second passage to maintain the sice and shape of said restricted second passage.
44. The graft of claim 43 wherein: the reinforcing means comprises a sleeve located about said means having a restricted second passage.
45. The graft of claim 43 wherein: the means having a restricted passage comprises a tubular wall joined to a converging wall and a diverging wall, said reinforc¬ ing means comprising a sleeve surrounding and mounted on the tubular wall, converging wall, and diverging wall.
46. The graft of claim 43 wherein: the means having a restricted passage comprises a synthetic tube, said reinforcing means including enlarged wall thickness of said tube to maintain the size and shape of said restricted passage.
47. A graft for supplying blood to one or more blood vessels comprising: an elongated means for carry¬ ing blood from a supply of blood under pressure to one or more blood vessels, said tubular means having body means providing a first passage for carrying blood, said body means being provided with one or more openings and connectable to at least one blood vessel for supplying blood through said one opening to said blood vessel, inlet end means adapted to be connected to the supply of blood under pressure whereby blood flows into said first passage and from said first passage into said blood vessel, means having a restricted second passage connected to said body means remote from said inlet

and means to control the flow of blood through the first passage and sustaining the pressure of the blood in the first passage, and an outlet end means connected to the means having the restricted second passage adapted to be connected to means for receiving blood having blood pressure lower than the pressure of the supply of blood.
48. The graft of claim 47 wherein: said body means has a U-shape.
49. The graft of claim 47 wherein: said elongated means is a synthetic tube.
50. The graft of claim 47 wherein: said elongated means is an umbilical cord.
51. The graft of claim 47 wherein: said body means and inlet end means comprises a saphenous vein, and said means having a restricted second passage comprises a tubular member having said second passage, and means connectable to said saphenous vein.
52. The graft of claim 47 wherein: said means having a restricted second passage includes clamp means located about a distal section thereby adjusting the size of said second passage.
53. The graft of claim 52 wherein: said clamp means includes means for adjusting the clamp means to vary the size of said distal section thereby adjusting the size of said second passage.
54. The graft of claim 47 including: reinforcing means cooperating with the means having a restricted second passage to maintain the size and shape of said restricted second passage.
55. The graft of claim 54 wherein: the reinforcing means comprises a sleeve located about said means having a restricted second passage.

56. The graft of claim 54 wherein: the means having a restricted passage comprises a synthetic tube, said reinforcing means including enlarged wall thickness of said tube to maintain the size and shape of said restricted passage.
57. A method for providing a continuous supply of flowing blood to blood receiving vessels of a living body with an elongated graft having an inlet end, an outlet end, a continuous passage extended from the inlet end to the outlet end for accommodating a continu¬ ous flow of blood and blood flow restriction means in the distal portion thereof for sustaining the pressure of the blood in the continuous passage comprising: securing the inlet end of the graft to a supply of blood under pressure by operation of the heart in a manner to allow blood to flow in said continuous passage, secur¬ ing at least one portion of the graft between the inlet end and restriction means to a blood receiving vessel in a manner to allow blood to flow from said continuous passage into said blood receiving vessel, and securing the outlet end of the graft to blood accommodating means having blood pressure less than the blood pressure of the supply of blood whereby a continuous flow of blood flows through said passage from the inlet to the outlet end thereof, said blood flow restriction means being operable to maintain flowing blood at a pressure in said continuous passage sufficient to perfuse the blood receiving vessel.
58. The method of claim 57 wherein: the inlet end of the graft is anastomosed to the aorta whereby blood from the aorta flows through said passage in the graft.
59. The method of claim 58 wherein: the outlet end of the graft is anastomosed to the atrium section of the heart whereby blood flows from the passage into the atrium chamber of the heart.

. e me o o c a m w re n a p of portions of the graft between the restriction means • and inlet end are anastomosed to separate coronary arteries.
61. The method of claim 57 wherein: the outlet end of the graft is anastomosed to the atrium section of the heart whereby blood flows from the passage into the atrium chamber of the heart.
62. The method of claim 57 including: adjusting the rate of flow of blood through said continuous pass¬ age with the blood flow restriction means.
OMPI

AU24182/84A
1982-12-13
1983-12-08
Vascular graft and blood supply method

Ceased

AU572819B2
(en)

Applications Claiming Priority (4)

Application Number
Priority Date
Filing Date
Title

US06/448,955

US4546499A
(en)

1982-12-13
1982-12-13
Method of supplying blood to blood receiving vessels

US489798

1983-04-29

US06/489,798

US4562597A
(en)

1982-12-13
1983-04-29
Method of supplying blood to blood receiving vessels

US448955

1983-04-29

Related Child Applications (1)

Application Number
Title
Priority Date
Filing Date

AU20375/88A
Division

AU609851B2
(en)

1982-12-13
1988-08-03
Vascular graft and blood supply method

Publications (2)

Publication Number
Publication Date

AU2418284A

AU2418284A
(en)

1984-07-05

AU572819B2
true

AU572819B2
(en)

1988-05-19

Family
ID=27035549
Family Applications (2)

Application Number
Title
Priority Date
Filing Date

AU24182/84A
Ceased

AU572819B2
(en)

1982-12-13
1983-12-08
Vascular graft and blood supply method

AU20375/88A
Ceased

AU609851B2
(en)

1982-12-13
1988-08-03
Vascular graft and blood supply method

Family Applications After (1)

Application Number
Title
Priority Date
Filing Date

AU20375/88A
Ceased

AU609851B2
(en)

1982-12-13
1988-08-03
Vascular graft and blood supply method

Country Status (23)

Country
Link

US
(3)

US4546499A
(en)

EP
(1)

EP0128215B1
(en)

JP
(1)

JPH0447576B2
(en)

AT
(1)

ATE51750T1
(en)

AU
(2)

AU572819B2
(en)

BE
(1)

BE900533A
(en)

BR
(1)

BR8307628A
(en)

CA
(1)

CA1238153A
(en)

DE
(1)

DE3390385C2
(en)

DK
(1)

DK385384A
(en)

ES
(1)

ES284576Y
(en)

FI
(1)

FI82371C
(en)

GB
(2)

GB2141939B
(en)

GR
(1)

GR79165B
(en)

IL
(1)

IL70370A
(en)

IT
(1)

IT1169976B
(en)

MX
(1)

MX159806A
(en)

NO
(1)

NO159338C
(en)

RU
(1)

RU2023438C1
(en)

SE
(1)

SE458660B
(en)

UA
(1)

UA7994A
(en)

WO
(1)

WO1984002266A1
(en)

ZA
(1)

ZA839229B
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU609851B2
(en)

*

1982-12-13
1991-05-09
Possis Medical, Inc.
Vascular graft and blood supply method

Families Citing this family (168)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4909979A
(en)

*

1983-03-24
1990-03-20
Possis Medical, Inc.
Method for making a vascular graft

AU592772B2
(en)

*

1984-09-05
1990-01-25
Vaso Products Australia Pty. Limited
Control of blood flow

EP0200286A3
(en)

*

1985-02-28
1987-01-14
Quotidian No. 100 Pty. Limited
Control of blood flow

EP0331725B1
(en)

*

1987-08-31
1994-12-28
Acculase, Inc.
Rare gas-halogen excimer laser

US4840940A
(en)

*

1987-10-21
1989-06-20
Sottiurai Vikrom S
Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin

US20060161173A1
(en)

*

1991-07-03
2006-07-20
Maginot Thomas J
Endoscopic bypass grafting method utilizing an inguinal approach

US5304220A
(en)

*

1991-07-03
1994-04-19
Maginot Thomas J
Method and apparatus for implanting a graft prosthesis in the body of a patient

US7033383B1
(en)

*

1991-07-03
2006-04-25
Cardiothoracic Systems, Inc.
Endoscopic bypass grafting method utilizing an inguinal approach

US7597697B1
(en)

*

1991-07-03
2009-10-06
Boston Scientific Scimed, Inc.
Bypass grafting method

US5211683A
(en)

*

1991-07-03
1993-05-18
Maginot Thomas J
Method of implanting a graft prosthesis in the body of a patient

GB9116563D0
(en)

*

1991-08-01
1991-09-18
Newtec Vascular Products Ltd
Vascular prosthesis ii

US5756035A
(en)

*

1991-08-01
1998-05-26
Polymedica Industries, Inc.
Method of making an access graft and a vascular prosthesis

US5662713A
(en)

1991-10-09
1997-09-02
Boston Scientific Corporation
Medical stents for body lumens exhibiting peristaltic motion

US5876445A
(en)

*

1991-10-09
1999-03-02
Boston Scientific Corporation
Medical stents for body lumens exhibiting peristaltic motion

US5211658A
(en)

*

1991-11-05
1993-05-18
New England Deaconess Hospital Corporation
Method and device for performing endovascular repair of aneurysms

CA2475058C
(en)

*

1992-10-13
2008-12-02
Boston Scientific Corporation
Medical stents for body lumens exhibiting peristaltic motion

US5429144A
(en)

*

1992-10-30
1995-07-04
Wilk; Peter J.
Coronary artery by-pass method

US5409019A
(en)

*

1992-10-30
1995-04-25
Wilk; Peter J.
Coronary artery by-pass method

US5425765A
(en)

1993-06-25
1995-06-20
Tiefenbrun; Jonathan
Surgical bypass method

US5632772A
(en)

*

1993-10-21
1997-05-27
Corvita Corporation
Expandable supportive branched endoluminal grafts

US5713950A
(en)

1993-11-01
1998-02-03
Cox; James L.
Method of replacing heart valves using flexible tubes

US5480424A
(en)

*

1993-11-01
1996-01-02
Cox; James L.
Heart valve replacement using flexible tubes

WO1997024083A1
(en)

*

1993-11-01
1997-07-10
Cox James L
Method of replacing heart valves using flexible tubes

US5476506A
(en)

*

1994-02-08
1995-12-19
Ethicon, Inc.
Bi-directional crimped graft

CA2147547C
(en)

1994-08-02
2006-12-19
Peter J. Schmitt
Thinly woven flexible graft

US5591226A
(en)

*

1995-01-23
1997-01-07
Schneider (Usa) Inc.
Percutaneous stent-graft and method for delivery thereof

US5683449A
(en)

*

1995-02-24
1997-11-04
Marcade; Jean Paul
Modular bifurcated intraluminal grafts and methods for delivering and assembling same

DE19508129C2
(en)

*

1995-03-08
1997-02-13
Jan Dr Med Menke

Blood flow adjustment device for optional external constriction and expansion of the blood flow cross section of a blood vessel

EP0955933B1
(en)

*

1995-10-13
2009-08-26
Medtronic Vascular, Inc.
A device for interstitial transvascular intervention

US6190353B1
(en)

*

1995-10-13
2001-02-20
Transvascular, Inc.
Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures

US20080221668A1
(en)

*

1995-11-13
2008-09-11
Boston Scientific Corp.
Expandable supportive branched endoluminal grafts

JP2750569B2
(en)

*

1995-12-07
1998-05-13
幸夫 堀口

Intravascular blood flow regulator and artificial blood vessel for bypass

DE69724255T2
(en)

*

1996-02-02
2004-06-03
Transvascular, Inc., Menlo Park

SYSTEM FOR INTERSTITIAL TRANSVASCULAR SURGICAL INTERVENTIONS

DE19604881A1
(en)

*

1996-02-10
1997-08-14
Klaus Prof Dr Ing Affeld
Mechanical prosthetic heart valve

US6273912B1
(en)

1996-02-28
2001-08-14
Impra, Inc.
Flanged graft for end-to-side anastomosis

DE69634278T2
(en)

*

1996-02-28
2006-01-05
Bard Peripheral Vascular, Inc., Tempe

FLANGED TRANSPLANT FOR END-TO-SIDE ANASTOMOSIS

US6190590B1
(en)

*

1996-02-28
2001-02-20
Impra, Inc.
Apparatus and method for making flanged graft for end-to-side anastomosis

US5782905A
(en)

*

1996-05-03
1998-07-21
Zuli Holdings Ltd.
Endovascular device for protection of aneurysm

US5662124A
(en)

*

1996-06-19
1997-09-02
Wilk Patent Development Corp.
Coronary artery by-pass method

US5755682A
(en)

*

1996-08-13
1998-05-26
Heartstent Corporation
Method and apparatus for performing coronary artery bypass surgery

EP0957822A4
(en)

*

1996-10-07
2001-04-11
Possis Medical Inc
Vascular graft

US5941908A
(en)

*

1997-04-23
1999-08-24
Vascular Science, Inc.
Artificial medical graft with a releasable retainer

US6155264A
(en)

*

1997-03-06
2000-12-05
Scimed Life Systems, Inc.
Percutaneous bypass by tunneling through vessel wall

US6035856A
(en)

1997-03-06
2000-03-14
Scimed Life Systems
Percutaneous bypass with branching vessel

US6026814A
(en)

*

1997-03-06
2000-02-22
Scimed Life Systems, Inc.
System and method for percutaneous coronary artery bypass

US7708769B1
(en)

1997-03-13
2010-05-04
United States Surgical Corporation
Graft attachment assembly

IL132195A0
(en)

*

1997-04-11
2001-03-19
Transvascular Inc
Method and apparatus for transmyocardial direct coronary revascularization

GB9709967D0
(en)

1997-05-17
1997-07-09
Harris Peter L
Prosthetic grafts

US6443158B1
(en)

1997-06-19
2002-09-03
Scimed Life Systems, Inc.
Percutaneous coronary artery bypass through a venous vessel

US6213126B1
(en)

1997-06-19
2001-04-10
Scimed Life Systems, Inc.
Percutaneous artery to artery bypass using heart tissue as a portion of a bypass conduit

US6092526A
(en)

*

1997-06-19
2000-07-25
Scimed Life Systems, Inc.
Percutaneous chamber-to-artery bypass

US5908029A
(en)

*

1997-08-15
1999-06-01
Heartstent Corporation
Coronary artery bypass with reverse flow

US5922022A
(en)

*

1997-09-04
1999-07-13
Kensey Nash Corporation
Bifurcated connector system for coronary bypass grafts and methods of use

US6063114A
(en)

*

1997-09-04
2000-05-16
Kensey Nash Corporation
Connector system for vessels, ducts, lumens or hollow organs and methods of use

US6187033B1
(en)

1997-09-04
2001-02-13
Meadox Medicals, Inc.
Aortic arch prosthetic graft

US6102941A
(en)

*

1997-10-06
2000-08-15
Heartstent Corporation
Transmyocardial implant with coronary ingrowth

US5984956A
(en)

*

1997-10-06
1999-11-16
Heartstent Corporation
Transmyocardial implant

US6371982B2
(en)

1997-10-09
2002-04-16
St. Jude Medical Cardiovascular Group, Inc.
Graft structures with compliance gradients

US6251418B1
(en)

1997-12-18
2001-06-26
C.R. Bard, Inc.
Systems and methods for local delivery of an agent

US6197324B1
(en)

1997-12-18
2001-03-06
C. R. Bard, Inc.
System and methods for local delivery of an agent

US6048362A
(en)

*

1998-01-12
2000-04-11
St. Jude Medical Cardiovascular Group, Inc.
Fluoroscopically-visible flexible graft structures

US6250305B1
(en)

1998-01-20
2001-06-26
Heartstent Corporation
Method for using a flexible transmyocardial implant

US6214041B1
(en)

1998-01-20
2001-04-10
Heartstent Corporation
Transmyocardial implant with septal perfusion

US6007576A
(en)

*

1998-02-06
1999-12-28
Mcclellan; Scott B.
End to side anastomic implant

US7027398B2
(en)

*

2001-04-12
2006-04-11
General Instrument Corporation
Method and apparatus for monitoring voice conversations from customer premises equipment

AU755190B2
(en)

*

1998-02-13
2002-12-05
Ventrica, Inc.
Methods and devices providing transmyocardial blood flow to the arterial vascular system of the heart

US6651670B2
(en)

*

1998-02-13
2003-11-25
Ventrica, Inc.
Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication

US20020144696A1
(en)

1998-02-13
2002-10-10
A. Adam Sharkawy
Conduits for use in placing a target vessel in fluid communication with a source of blood

US6808498B2
(en)

1998-02-13
2004-10-26
Ventrica, Inc.
Placing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber

US6235054B1
(en)

1998-02-27
2001-05-22
St. Jude Medical Cardiovascular Group, Inc.
Grafts with suture connectors

US6325813B1
(en)

1998-08-18
2001-12-04
Scimed Life Systems, Inc.
Method and apparatus for stabilizing vascular wall

US6254564B1
(en)

1998-09-10
2001-07-03
Percardia, Inc.
Left ventricular conduit with blood vessel graft

US6689121B1
(en)

1998-09-24
2004-02-10
C. R. Bard, Inc.
Systems and methods for treating ischemia

US6432126B1
(en)

1998-09-30
2002-08-13
C.R. Bard, Inc.
Flexible vascular inducing implants

US6458092B1
(en)

1998-09-30
2002-10-01
C. R. Bard, Inc.
Vascular inducing implants

US6248112B1
(en)

1998-09-30
2001-06-19
C. R. Bard, Inc.
Implant delivery system

US6692520B1
(en)

1998-12-15
2004-02-17
C. R. Bard, Inc.
Systems and methods for imbedded intramuscular implants

US7025773B2
(en)

1999-01-15
2006-04-11
Medtronic, Inc.
Methods and devices for placing a conduit in fluid communication with a target vessel

US7578828B2
(en)

1999-01-15
2009-08-25
Medtronic, Inc.
Methods and devices for placing a conduit in fluid communication with a target vessel

US6409697B2
(en)

*

1999-05-04
2002-06-25
Heartstent Corporation
Transmyocardial implant with forward flow bias

US6182668B1
(en)

1999-05-13
2001-02-06
Heartstent Corporation
Transmyocardial implant with induced tissue flap

US6986784B1
(en)

1999-05-14
2006-01-17
C. R. Bard, Inc.
Implant anchor systems

US6253768B1
(en)

*

1999-08-04
2001-07-03
Percardia, Inc.
Vascular graft bypass

US6855160B1
(en)

1999-08-04
2005-02-15
C. R. Bard, Inc.
Implant and agent delivery device

US20080018016A1
(en)

*

1999-09-10
2008-01-24
Rapacki Alan R
Manufacturing conduits for use in placing a target vessel in fluid communication with a source of blood

US6635214B2
(en)

*

1999-09-10
2003-10-21
Ventrica, Inc.
Manufacturing conduits for use in placing a target vessel in fluid communication with a source of blood

US6592567B1
(en)

1999-12-07
2003-07-15
Chf Solutions, Inc.
Kidney perfusion catheter

US8092511B2
(en)

2000-03-03
2012-01-10
Endovascular Technologies, Inc.
Modular stent-graft for endovascular repair of aortic arch aneurysms and dissections

US6814752B1
(en)

2000-03-03
2004-11-09
Endovascular Technologies, Inc.
Modular grafting system and method

IL153753A0
(en)

*

2002-12-30
2003-07-06
Neovasc Medical Ltd
Varying-diameter vascular implant and balloon

US6953476B1
(en)

*

2000-03-27
2005-10-11
Neovasc Medical Ltd.
Device and method for treating ischemic heart disease

US7666221B2
(en)

2000-05-01
2010-02-23
Endovascular Technologies, Inc.
Lock modular graft component junctions

US7232421B1
(en)

2000-05-12
2007-06-19
C. R. Bard, Inc.
Agent delivery systems

US7204847B1
(en)

2000-07-28
2007-04-17
C. R. Bard, Inc.
Implant anchor systems

US20020123786A1
(en)

*

2001-03-02
2002-09-05
Ventrica, Inc.
Methods and devices for bypassing an obstructed target vessel by placing the vessel in communication with a heart chamber containing blood

US20060052821A1
(en)

2001-09-06
2006-03-09
Ovalis, Inc.
Systems and methods for treating septal defects

US6776784B2
(en)

2001-09-06
2004-08-17
Core Medical, Inc.
Clip apparatus for closing septal defects and methods of use

US6702835B2
(en)

2001-09-07
2004-03-09
Core Medical, Inc.
Needle apparatus for closing septal defects and methods for using such apparatus

JP4398244B2
(en)

2001-10-04
2010-01-13
ネオヴァスク メディカル リミテッド

Flow reduction implant

US6942672B2
(en)

2001-10-23
2005-09-13
Vascor, Inc.
Method and apparatus for attaching a conduit to the heart or a blood vessel

RU2341296C2
(en)

2002-05-24
2008-12-20
Энджиотек Интернэшнл Аг
Compositions and methods of medical implant covering

US20030181843A1
(en)

*

2002-06-11
2003-09-25
Scout Medical Technologies, Llc
Device and method providing arterial blood flow for perfusion of ischemic myocardium

US20060106449A1
(en)

*

2002-08-08
2006-05-18
Neovasc Medical Ltd.
Flow reducing implant

AU2003219503A1
(en)

*

2002-08-08
2004-02-25
Neovasc Medical Ltd.
Geometric flow regulator

US8535370B1
(en)

2003-01-23
2013-09-17
Endovascular Technologies, Inc.
Radiopaque markers for endovascular graft alignment

WO2004093937A2
(en)

*

2003-04-23
2004-11-04
Interrad Medical, Inc.
Dialysis valve and method

US20040215125A1
(en)

*

2003-04-27
2004-10-28
Brown Donald W.
Bifurcated graft for dialysis

US20040228411A1
(en)

*

2003-05-12
2004-11-18
Sony Corporation
Method and system for decoder clock control in presence of jitter

US7566317B1
(en)

*

2003-07-07
2009-07-28
Stanley Batiste
A-V dialysis graft

US6986751B2
(en)

*

2003-08-05
2006-01-17
Cabg Medical, Inc.
Grafted network incorporating a multiple channel fluid flow connector

US7011643B2
(en)

2003-08-05
2006-03-14
Cabg Medical, Inc.
Grafted network incorporating a multiple channel fluid flow connector

US6991615B2
(en)

*

2003-08-05
2006-01-31
Cabg Medical, Inc.
Grafted network incorporating a multiple channel fluid flow connector

US7235083B1
(en)

2003-09-10
2007-06-26
Endovascular Technologies, Inc.
Methods and devices for aiding in situ assembly of repair devices

US20050288618A1
(en)

*

2004-06-24
2005-12-29
Scimed Life Systems, Inc.
Myocardial treatment apparatus and method

US20060047337A1
(en)

*

2004-08-27
2006-03-02
Brenneman Rodney A
Device and method for establishing an artificial arterio-venous fistula

US9706997B2
(en)

2004-08-27
2017-07-18
Rox Medical, Inc.
Device and method for establishing an artificial arterio-venous fistula

US7828814B2
(en)

*

2004-08-27
2010-11-09
Rox Medical, Inc.
Device and method for establishing an artificial arterio-venous fistula

US8226592B2
(en)

*

2004-12-15
2012-07-24
Rox Medical, Inc.
Method of treating COPD with artificial arterio-venous fistula and flow mediating systems

DE102005003632A1
(en)

2005-01-20
2006-08-17
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

Catheter for the transvascular implantation of heart valve prostheses

EP1693025A1
(en)

*

2005-02-17
2006-08-23
Universität Zürich
Method of manufacturing a tissue-engineered prosthesis

US20060195178A1
(en)

*

2005-02-28
2006-08-31
Stephen West
Aneurismal sack deflator

EP1912679A4
(en)

*

2005-06-15
2009-07-29
Massachusetts Inst Technology
Amine-containing lipids and uses thereof

US8709069B2
(en)

*

2005-07-01
2014-04-29
C. R. Bard, Inc.
Flanged graft with trim lines

US8579936B2
(en)

2005-07-05
2013-11-12
ProMed, Inc.
Centering of delivery devices with respect to a septal defect

US7846179B2
(en)

2005-09-01
2010-12-07
Ovalis, Inc.
Suture-based systems and methods for treating septal defects

US7568753B2
(en)

*

2006-06-15
2009-08-04
Mattel, Inc.
Children’s ride-on vehicles with reconfigured bodies and methods for forming the same

SE530226C2
(en)

*

2006-08-15
2008-04-01
Gestamp Hardtech Ab

Bumper beam for vehicles

US20080051879A1
(en)

*

2006-08-23
2008-02-28
Cook Incorporated
Methods of treating venous valve related conditions with a flow-modifying implantable medical device

US7896915B2
(en)

2007-04-13
2011-03-01
Jenavalve Technology, Inc.
Medical device for treating a heart valve insufficiency

US20100280598A1
(en)

*

2007-12-27
2010-11-04
C.R. Bard, Inc.
Vascular graft prosthesis having a reinforced margin for enhanced anastomosis

WO2009086548A1
(en)

*

2007-12-31
2009-07-09
C.R. Bard, Inc.
Vascular graft prosthesis with selective flow reduction

US9044318B2
(en)

2008-02-26
2015-06-02
Jenavalve Technology Gmbh
Stent for the positioning and anchoring of a valvular prosthesis

ES2903231T3
(en)

2008-02-26
2022-03-31
Jenavalve Tech Inc

Stent for positioning and anchoring a valve prosthesis at an implantation site in a patient’s heart

ITMI20080643A1
(en)

*

2008-04-11
2009-10-12
Fin Ceramica Faenza Spa

METHOD OF PERFONDING A GRAFT OF BIOCOMPATIBLE MATERIAL WITH A LIQUID AND PERFUSION KIT

WO2010039862A1
(en)

*

2008-09-30
2010-04-08
Rox Medical, Inc.
Methods for screening and treating patients with compromised cardiopulmonary function

EP2365962B1
(en)

2008-11-07
2017-07-05
Massachusetts Institute of Technology
Aminoalcohol lipidoids and uses thereof

CN102282751B
(en)

*

2009-01-16
2014-04-16
Abb技术有限公司
Fault protection in voltage source converters with redundant switching cells via mechanical switches being closed pyrotechnically

PL3338765T3
(en)

2009-12-01
2019-06-28
Translate Bio, Inc.
Steroid derivative for the delivery of mrna in human genetic diseases

BR112012029896A2
(en)

2010-05-25
2017-06-20
Jenavalve Tech Inc

prosthetic heart valve for stent graft and stent graft

WO2012027675A2
(en)

2010-08-26
2012-03-01
Massachusetts Institute Of Technology
Poly(beta-amino alcohols), their preparation, and uses thereof

PL2691443T3
(en)

2011-03-28
2021-08-30
Massachusetts Institute Of Technology
Conjugated lipomers and uses thereof

CN111671919A
(en)

2011-06-08
2020-09-18
川斯勒佰尔公司
Lipid nanoparticle compositions and methods for MRNA delivery

RU2466695C1
(en)

*

2011-07-22
2012-11-20
Закрытое Акционерное Общество Научно-Производственное Предприятие “Мединж”
Valve-containing pulmonary arterial graft

US20150267192A1
(en)

2012-06-08
2015-09-24
Shire Human Genetic Therapies, Inc.
Nuclease resistant polynucleotides and uses thereof

MX365409B
(en)

2013-03-14
2019-05-31
Shire Human Genetic Therapies
Cftr mrna compositions and related methods and uses.

EP3467108A1
(en)

2013-03-14
2019-04-10
Translate Bio, Inc.
Methods for purification of messenger rna

US9315472B2
(en)

2013-05-01
2016-04-19
Massachusetts Institute Of Technology
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof

CN105491978A
(en)

2013-08-30
2016-04-13
耶拿阀门科技股份有限公司
Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame

CA2928188A1
(en)

2013-10-22
2015-04-30
Shire Human Genetic Therapies, Inc.
Mrna therapy for argininosuccinate synthetase deficiency

EA034103B1
(en)

2013-10-22
2019-12-27
Транслейт Био, Инк.
METHOD OF TREATING PHENYLKETONURIA USING mRNA

EA201690576A1
(en)

2013-10-22
2016-10-31
Шир Хьюман Дженетик Терапис, Инк.

LIPID COMPOSITIONS FOR DELIVERY OF MATRIX RNA

KR20220158867A
(en)

2014-04-25
2022-12-01
샤이어 휴먼 지네틱 테라피즈 인크.
Methods for purification of messenger rna

BR112016027705A2
(en)

2014-05-30
2018-01-30
Shire Human Genetic Therapies

biodegradable lipids for nucleic acid delivery

PE20171238A1
(en)

2014-06-24
2017-08-24
Shire Human Genetic Therapies

STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR NUCLEIC ACIDS ADMINISTRATION

EP3164379A1
(en)

2014-07-02
2017-05-10
Massachusetts Institute of Technology
Polyamine-fatty acid derived lipidoids and uses thereof

US10667931B2
(en)

*

2014-07-20
2020-06-02
Restore Medical Ltd.
Pulmonary artery implant apparatus and methods of use thereof

WO2016154452A2
(en)

2015-03-24
2016-09-29
Osiris Therapeutics, Inc.
Compositions comprising meniscal tissues and uses thereof

US10709555B2
(en)

2015-05-01
2020-07-14
Jenavalve Technology, Inc.
Device and method with reduced pacemaker rate in heart valve replacement

EP4183371A1
(en)

2016-05-13
2023-05-24
JenaValve Technology, Inc.
Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system

US11771434B2
(en)

2016-09-28
2023-10-03
Restore Medical Ltd.
Artery medical apparatus and methods of use thereof

CN110392557A
(en)

2017-01-27
2019-10-29
耶拿阀门科技股份有限公司
Heart valve simulation

MX2019010155A
(en)

2017-02-27
2020-12-10
Translate Bio Inc
Novel codon-optimized cftr mrna.

EP3624824A1
(en)

2017-05-16
2020-03-25
Translate Bio, Inc.
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr

EP3624704A4
(en)

2017-06-05
2021-03-10
Restore Medical Ltd
Double walled fixed length stent like apparatus and methods of use thereof

JP7090156B2
(en)

2017-12-01
2022-06-23
シー・アール・バード・インコーポレーテッド

Artificial medical device

KR20210060480A
(en)

2018-08-24
2021-05-26
트랜슬레이트 바이오 인코포레이티드

Method for purifying messenger RNA

US20200121845A1
(en)

*

2018-10-19
2020-04-23
Stan Batiste
AV Flow Restrictors

WO2020154517A1
(en)

2019-01-23
2020-07-30
Neovasc Medical Ltd.
Covered flow modifying apparatus

Family Cites Families (19)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US2127903A
(en)

*

1936-05-05
1938-08-23
Davis & Geck Inc
Tube for surgical purposes and method of preparing and using the same

US3096560A
(en)

*

1958-11-21
1963-07-09
William J Liebig
Process for synthetic vascular implants

US3029819A
(en)

*

1959-07-30
1962-04-17
J L Mcatee
Artery graft and method of producing artery grafts

US3166688A
(en)

*

1962-11-14
1965-01-19
Ronald P Rowand
Polytetrafluoroethylene tubing having electrically conductive properties

GB1104680A
(en)

*

1965-10-18
1968-02-28
Univ Birmingham
Artificial artery

US3570013A
(en)

*

1968-06-19
1971-03-16
Louis J Blumen
Cardiac implant

US3626947A
(en)

*

1970-02-19
1971-12-14
Charles Howard Sparks
Method and apparatus for vein and artery reenforcement

US3667069A
(en)

*

1970-03-27
1972-06-06
Univ Minnesota
Jet pump cardiac replacement and assist device and method of at least partially replacing a disabled right heart

US3730186A
(en)

*

1971-03-05
1973-05-01
Univ California
Adjustable implantable artery-constricting device

US3945052A
(en)

*

1972-05-01
1976-03-23
Meadox Medicals, Inc.
Synthetic vascular graft and method for manufacturing the same

US3805301A
(en)

*

1972-07-28
1974-04-23
Meadox Medicals Inc
Tubular grafts having indicia thereon

US3894530A
(en)

*

1973-07-06
1975-07-15
Irving I Dardik
Method for repairing, augmenting, or replacing a body conduit or organ

US3988782A
(en)

*

1973-07-06
1976-11-02
Dardik Irving I
Non-antigenic, non-thrombogenic infection-resistant grafts from umbilical cord vessels and process for preparing and using same

US3974526A
(en)

*

1973-07-06
1976-08-17
Dardik Irving I
Vascular prostheses and process for producing the same

US3882862A
(en)

*

1974-01-11
1975-05-13
Olga Berend
Arteriovenous shunt

JPS6037735B2
(en)

*

1978-10-18
1985-08-28
住友電気工業株式会社

Artificial blood vessel

US4240794A
(en)

*

1979-06-25
1980-12-23
Beisang Arthur A
Method of preforming vascular grafts of human and other animal origin

US4356571A
(en)

*

1979-10-12
1982-11-02
Robert Bosch Gmbh
Prosthetic device

US4546499A
(en)

*

1982-12-13
1985-10-15
Possis Medical, Inc.
Method of supplying blood to blood receiving vessels

1982

1982-12-13
US
US06/448,955
patent/US4546499A/en
not_active
Expired – Lifetime

1983

1983-04-29
US
US06/489,798
patent/US4562597A/en
not_active
Expired – Lifetime

1983-12-02
IL
IL70370A
patent/IL70370A/en
not_active
IP Right Cessation

1983-12-08
GB
GB08418112A
patent/GB2141939B/en
not_active
Expired

1983-12-08
AU
AU24182/84A
patent/AU572819B2/en
not_active
Ceased

1983-12-08
DE
DE3390385T
patent/DE3390385C2/en
not_active
Expired – Fee Related

1983-12-08
UA
UA3781694A
patent/UA7994A/en
unknown

1983-12-08
AT
AT84900426T
patent/ATE51750T1/en
not_active
IP Right Cessation

1983-12-08
EP
EP84900426A
patent/EP0128215B1/en
not_active
Expired – Lifetime

1983-12-08
JP
JP59500488A
patent/JPH0447576B2/ja
not_active
Expired – Lifetime

1983-12-08
MX
MX199662A
patent/MX159806A/en
unknown

1983-12-08
WO
PCT/US1983/001932
patent/WO1984002266A1/en
active
IP Right Grant

1983-12-08
BR
BR8307628A
patent/BR8307628A/en
not_active
IP Right Cessation

1983-12-12
ES
ES1983284576U
patent/ES284576Y/en
not_active
Expired

1983-12-12
ZA
ZA839229A
patent/ZA839229B/en
unknown

1983-12-12
CA
CA000443106A
patent/CA1238153A/en
not_active
Expired

1983-12-13
GR
GR73227A
patent/GR79165B/el
unknown

1983-12-13
IT
IT24139/83A
patent/IT1169976B/en
active

1984

1984-07-13
US
US06/630,838
patent/US4601718A/en
not_active
Expired – Lifetime

1984-08-09
SE
SE8404046A
patent/SE458660B/en
not_active
IP Right Cessation

1984-08-10
NO
NO84843201A
patent/NO159338C/en
unknown

1984-08-10
DK
DK385384A
patent/DK385384A/en
not_active
Application Discontinuation

1984-08-10
RU
SU843781696A
patent/RU2023438C1/en
active

1984-08-13
FI
FI843186A
patent/FI82371C/en
not_active
IP Right Cessation

1984-09-07
BE
BE0/213618A
patent/BE900533A/en
not_active
IP Right Cessation

1986

1986-02-03
GB
GB08602617A
patent/GB2169208B/en
not_active
Expired

1988

1988-08-03
AU
AU20375/88A
patent/AU609851B2/en
not_active
Ceased

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU609851B2
(en)

*

1982-12-13
1991-05-09
Possis Medical, Inc.
Vascular graft and blood supply method

Also Published As

Publication number
Publication date

IL70370A0
(en)

1984-03-30

FI82371B
(en)

1990-11-30

GB8602617D0
(en)

1986-03-12

DE3390385C2
(en)

1994-07-07

ATE51750T1
(en)

1990-04-15

BE900533A
(en)

1985-01-02

GB2169208B
(en)

1987-05-20

GB2141939A
(en)

1985-01-09

ES284576Y
(en)

1986-12-01

UA7994A
(en)

1995-12-26

ZA839229B
(en)

1984-08-29

DK385384A
(en)

1984-08-28

IL70370A
(en)

1990-04-29

ES284576U
(en)

1986-03-01

BR8307628A
(en)

1984-11-27

AU609851B2
(en)

1991-05-09

GR79165B
(en)

1984-10-02

IT8324139A1
(en)

1985-06-13

DE3390385T1
(en)

1985-02-21

US4546499A
(en)

1985-10-15

FI843186A0
(en)

1984-08-13

GB2169208A
(en)

1986-07-09

IT1169976B
(en)

1987-06-03

EP0128215B1
(en)

1990-04-11

AU2418284A
(en)

1984-07-05

NO159338B
(en)

1988-09-12

JPH0447576B2
(en)

1992-08-04

EP0128215A1
(en)

1984-12-19

AU2037588A
(en)

1988-11-03

DK385384D0
(en)

1984-08-10

GB8418112D0
(en)

1984-08-22

NO843201L
(en)

1984-08-10

IT8324139D0
(en)

1983-12-13

MX159806A
(en)

1989-08-31

WO1984002266A1
(en)

1984-06-21

SE8404046D0
(en)

1984-08-09

US4562597A
(en)

1986-01-07

US4601718A
(en)

1986-07-22

FI82371C
(en)

1991-03-11

FI843186A
(en)

1984-08-13

EP0128215A4
(en)

1986-07-17

RU2023438C1
(en)

1994-11-30

CA1238153A
(en)

1988-06-21

GB2141939B
(en)

1987-05-20

SE8404046L
(en)

1984-08-09

NO159338C
(en)

1988-12-21

SE458660B
(en)

1989-04-24

JPS60500244A
(en)

1985-02-28

Similar Documents

Publication
Publication Date
Title

AU572819B2
(en)

1988-05-19

Vascular graft and blood supply method

US4441215A
(en)

1984-04-10

Vascular graft

US5849036A
(en)

1998-12-15

Vascular graft prosthesis

CN103200975B
(en)

2017-03-22

anastomotic device

US8882822B2
(en)

2014-11-11

Non-thrombogenic stent jacket

CN104367400B
(en)

2017-02-15

Stent graft

WO1982001647A1
(en)

1982-05-27

Vascular graft

KR20010006271A
(en)

2001-01-26

Endovascular graft for repairing abdominal aortic aneurysms

CN113597291A
(en)

2021-11-02

Flow regulating device in body cavity

Kenney et al.

1982

Comparison of noncrimped, externally supported (EXS) and crimped, nonsupported Dacron prostheses for axillofemoral and above-knee femoropopliteal bypass

CN109833112A
(en)

2019-06-04

Bracket and its application method in a kind of art

US20080161839A1
(en)

2008-07-03

Device and Method for Coronary Artery Bypass Procedure

EP3510973B1
(en)

2020-09-09

Vascular graft

RU187447U1
(en)

2019-03-06

Biological prosthesis of arteries with an external mesh tubular coating of the external wall

EP0957822A1
(en)

1999-11-24

Vascular graft

US10893929B2
(en)

2021-01-19

Vascular graft with compartments for compliance matching

CN110974484A
(en)

2020-04-10

Endoluminal prosthetic device for optimizing branch blood flow distribution

Harloff

1995

Are Biomaterials the Limiting Factor in the Progress of Arterial Prostheses?

Watanuki et al.

1978

Experimental studies of a nonwoven vascular prosthesis for use in small arteries

JPH0614941B2
(en)

1994-03-02

Multi-branch vascular prosthesis for coronary artery bypass

Download PDF in English